Seed · Biotech · London, United Kingdom · Founded 2017 · 15–27 employees
Sixfold Bioscience is developing programmable RNA delivery systems using their patented Mergo platform, which harnesses computation and advanced chemistry to deliver therapeutics to diseased cells beyond the liver. The company focuses on delivering siRNA for gene silencing and mRNA for gene expression to currently inaccessible cell types using bio-inspired delivery pathways. Founded by Forbes 30 Under 30 alumni and Y Combinator graduates, the company raised $10.5M in seed funding from investors including Cantos Ventures, Y Combinator, and Pi Campus in December 2021. They have strategic collaborations with Imperial College London, UCL, and the NIH.
No open roles listed right now.